These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

54 related articles for article (PubMed ID: 1518886)

  • 1. Controlled-release tablet formulation of isoniazid.
    Jain NK; Kulkarni K; Talwar N
    Pharmazie; 1992 Apr; 47(4):277-8. PubMed ID: 1518886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral matrix tablet formulations for concomitant controlled release of anti-tubercular drugs: design and in vitro evaluations.
    Hiremath PS; Saha RN
    Int J Pharm; 2008 Oct; 362(1-2):118-25. PubMed ID: 18640251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Formulation and in vitro/in vivo investigation of carbamazepine controlled-release matrix tablets.
    Ikinci G; Capan Y; Senel S; Dalkara T; Hincal AA
    Pharmazie; 1999 Feb; 54(2):139-41. PubMed ID: 10084159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel sustained release, swellable and bioadhesive gastroretentive drug delivery system for ofloxacin.
    Chavanpatil MD; Jain P; Chaudhari S; Shear R; Vavia PR
    Int J Pharm; 2006 Jun; 316(1-2):86-92. PubMed ID: 16567072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The effects of various factors on the in vitro velocity of drug release from repository tablets. Part 4: Isoniazid (Rimicid) respository tablets (author's transl)].
    Tomassini L; Michailova D; Naplatanova D; Slavtschev P
    Pharmazie; 1979 Dec; 34(12):812-4. PubMed ID: 545350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained release isoniazid tablets. I--Formulation and in vitro evaluation.
    Bulut-Oner F; Capan Y; Kas S; Oner L; Hincal AA
    Farmaco; 1989; 44(7-8):739-52. PubMed ID: 2590371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of theophylline sustained release dosage form based on Kollidon SR.
    Reza MS; Quadir MA; Haider SS
    Pak J Pharm Sci; 2002 Jan; 15(1):63-70. PubMed ID: 16414869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preparation and in vitro evaluation of sustained release tablet formulations of diclofenac sodium.
    Savaşer A; Ozkan Y; Işimer A
    Farmaco; 2005 Feb; 60(2):171-7. PubMed ID: 15752476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of khaya gum as a directly compressible matrix system for controlled release.
    Odeku OA; Fell JT
    J Pharm Pharmacol; 2004 Nov; 56(11):1365-70. PubMed ID: 15525442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Floating matrix dosage form for phenoporlamine hydrochloride based on gas forming agent: in vitro and in vivo evaluation in healthy volunteers.
    Xu X; Sun M; Zhi F; Hu Y
    Int J Pharm; 2006 Mar; 310(1-2):139-45. PubMed ID: 16413710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro dissolution and in vivo oral absorption of methylphenidate from a bimodal release formulation in healthy volunteers.
    Wang Y; Lee L; Somma R; Thompson G; Bakhtiar R; Lee J; Rekhi GS; Lau H; Sedek G; Hossain M
    Biopharm Drug Dispos; 2004 Mar; 25(2):91-8. PubMed ID: 14872557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Controlled release hydrophilic matrix tablet formulations of isoniazid: design and in vitro studies.
    Hiremath PS; Saha RN
    AAPS PharmSciTech; 2008; 9(4):1171-8. PubMed ID: 19015997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Formulation, release characteristics and bioavailability of novel monolithic hydroxypropylmethylcellulose matrix tablets containing acetaminophen.
    Cao QR; Choi YW; Cui JH; Lee BJ
    J Control Release; 2005 Nov; 108(2-3):351-61. PubMed ID: 16154656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preparation and evaluation of a novel delayed-onset sustained-release system of propranolol hydrochloride.
    Feng XM; Ren Q; Zhang WZ; Shen HF; Rong ZX; Fang C; Chen HZ
    J Pharm Pharmacol; 2008 Jul; 60(7):817-22. PubMed ID: 18549667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Formulation of a extended release tablet containing dexibuprofen.
    Yi HG; Chi MH; Kim YI; Woo JS; Park ES
    Arch Pharm Res; 2008 Dec; 31(12):1637-43. PubMed ID: 19099235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative bioavailability of a metoprolol controlled release formulation and a bisoprolol normal release tablet after single oral dose administration in healthy volunteers.
    Deroubaix X; Lins RL; Lens S; Demblon C; Jeanbaptiste B; Poelaert D; Stockis A
    Int J Clin Pharmacol Ther; 1996 Feb; 34(2):61-70. PubMed ID: 8929748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modified guar gum matrix tablet for controlled release of diltiazem hydrochloride.
    Toti US; Aminabhavi TM
    J Control Release; 2004 Mar; 95(3):567-77. PubMed ID: 15023467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Formulation of sustained - release lithium carbonate matrix tablets: influence of hydrophilic materials on the release rate and in vitro-in vivo evaluation.
    Emami J; Tavakoli N; Movahedian A
    J Pharm Pharm Sci; 2004 Nov; 7(3):338-44. PubMed ID: 15576014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Irregular absorption profiles observed from diclofenac extended release tablets can be predicted using a dissolution test apparatus that mimics in vivo physical stresses.
    Garbacz G; Wedemeyer RS; Nagel S; Giessmann T; Mönnikes H; Wilson CG; Siegmund W; Weitschies W
    Eur J Pharm Biopharm; 2008 Oct; 70(2):421-8. PubMed ID: 18582568
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Formulation and characterization of modified release tablets containing isoniazid using swellable polymers.
    Akhtar MF; Rabbani M; Sharif A; Akhtar B; Saleem A; Murtaza G
    Afr J Tradit Complement Altern Med; 2011; 8(3):250-9. PubMed ID: 22468003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.